
SynteractHCR Launches Intelligent Clinical Development Platform at DIA 2013 to Support Trial Efficiencies Globally
SynteractHCR’s goal is to take time and cost out of the drug development process and deliver successful therapies to patients sooner. ICD+ is the platform by which the company leverages clinical development expertise, appropriate technology and optimized processes, tailored to each client’s needs, to drive solution-oriented efficiencies on a global scale. ICD+ allows sponsors to get to decision points faster, while providing a uniform approach to trials globally to promote consistent standards and high quality.
“As we strive to streamline clinical trials and deliver better therapies in healthcare, we are confident that with ICD+, we offer a great solution to our clients,” says SynteractHCR CEO Wendel Barr. “We collaborate with our clients to meet their project objectives, deliver timely results, and provide high quality work that exceeds their expectations, and ICD+ is the efficient approach we use to guide the process.”
In addition, two managers from SynteractHCR will speak on Wednesday, June 26:
Director of IT Services Toby Odenheim, MBA, will give insights on “
Senior Manager of Clinical Operations Shyla Van Reenen will participate in a study startup symposium and present “
In March, 2013
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.





.png)



.png)



.png)
.png)
